{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:17:02Z","timestamp":1778606222341,"version":"3.51.4"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>To properly assess an association between vaccines and specific adverse events requires a comparison between the observed and background rates; however, studies in South Korea are currently limited. Therefore, in this study, we estimated the background incidence of anaphylaxis, myocarditis, pericarditis, Guillain-Barr\u00e9 syndrome (GBS), and mortality in South Korea.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective cohort study was conducted using the National Sample Cohort (NSC) data. Using NSC, the background incidence rate was estimated by dividing the number of episodes during 2009\u20132019 by the total population by year and then multiplying by 100,000. Using Statistics Korea data, the background mortality rate was estimated by dividing the number of deaths, during 2009\u20132019 by the standard population for that year and then multiplying by 100,000. Using background mortality rates, we predicted mortality rates for 2021 using autoregressive integrated moving average models. Further, the expected mortality rates were compared with observed mortality rates.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The age-adjusted incidence rate (AIR) of anaphylaxis increased from 4.28 to 22.90 cases per 100,000 population (p = 0.003); myocarditis showed no significant increase, changing from 0.56 to 1.26 cases per 100,000 population (p = 0.276); pericarditis increased from 0.94 to 1.88 cases per 100,000 population (p = 0.005); and GBS increased from 0.78 to 1.21 cases per 100,000 population (p = 0.013). The age-adjusted mortality rate decreased from 645.24 to 475.70 deaths per 100,000 population (p &lt;0.001). The 2021 observed\/expected mortality rates for overall (ratio: 1.08, 95% confidence interval [CI]: 1.07\u20131.08), men (ratio: 1.07, 95% CI: 1.07\u20131.08), and women (ratio: 1.08, 95% CI: 1.07\u20131.09), were all significantly higher. When stratified by age group, those aged \u226580 (ratio: 1.16, 95% CI: 1.15\u20131.17), 60\u201369 (ratio: 1.11, 95% CI: 1.10\u20131.13), and 20\u201329 years old (ratio: 1.07, 95% CI: 1.02\u20131.13) were also significantly higher.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Through the estimation of background rates related to anaphylaxis, myocarditis, pericarditis, GBS, and mortality, we established a reference point for evaluating the potential excess occurrence of adverse events following COVID-19 vaccination. This reference point serves as substantive evidence supporting the safety profile of COVID-19 vaccines.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0297902","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T18:26:41Z","timestamp":1708540001000},"page":"e0297902","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barr\u00e9 Syndrome, and mortality in South Korea using a nationwide population-based cohort study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-3212","authenticated-orcid":true,"given":"Hye Su","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-8916","authenticated-orcid":true,"given":"Byung Chul","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"2","key":"pone.0297902.ref001","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines9020160","article-title":"COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates.","volume":"9","author":"M. Sallam","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"pone.0297902.ref002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1983389","article-title":"Socio-demographic, psychological, and experiential predictors of COVID-19 vaccine hesitancy in South Korea, October-December 2020.","volume":"18","author":"SE Hwang","year":"2022","journal-title":"Hum Vaccin Immunother."},{"issue":"19","key":"pone.0297902.ref003","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"SB Black","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"pone.0297902.ref004","doi-asserted-by":"crossref","first-page":"e0210833","DOI":"10.1371\/journal.pone.0210833","article-title":"Demonstration of background rates of three conditions of interest for vaccine safety surveillance","volume":"14","author":"AE Wormsbecker","year":"2019","journal-title":"PLoS One"},{"issue":"28","key":"pone.0297902.ref005","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"D Gubernot","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"pone.0297902.ref006","doi-asserted-by":"crossref","first-page":"e0256379","DOI":"10.1371\/journal.pone.0256379","article-title":"The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan.","volume":"16","author":"T Sobue","year":"2021","journal-title":"PLoS One"},{"key":"pone.0297902.ref007","article-title":"Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study.","author":"X Li","year":"2021","journal-title":"medRxiv"},{"issue":"16","key":"pone.0297902.ref008","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barre Syndrome, February-July 2021","volume":"326","author":"EJ Woo","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"pone.0297902.ref009","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.","volume":"5","author":"KE Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"25","key":"pone.0297902.ref010","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).","volume":"39","author":"KJ Welsh","year":"2021","journal-title":"Vaccine"},{"key":"pone.0297902.ref011","article-title":"Guide to sample cohort DB.","author":"NHIS","journal-title":"In: NHIS web sites [Internet]."},{"key":"pone.0297902.ref012","article-title":"Korean statisitcal information service.","author":"Statistics Korea","journal-title":"In: Statistics Korea web sites [Internet]"},{"key":"pone.0297902.ref013","article-title":"Trends in occurrence of adverse reactions in Korea.","author":"KCDA","journal-title":"In: KCDA websites [Internet]"},{"issue":"5","key":"pone.0297902.ref014","doi-asserted-by":"crossref","first-page":"e5750","DOI":"10.1097\/MD.0000000000005750","article-title":"True rise in anaphylaxis incidence: Epidemiologic study based on a national health insurance database.","volume":"96","author":"MS Yang","year":"2017","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"pone.0297902.ref015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4168\/aair.2015.7.1.22","article-title":"Predictors of the Severity and Serious Outcomes of Anaphylaxis in Korean Adults: A Multicenter Retrospective Case Study","volume":"7","author":"Y Ye","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"issue":"10","key":"pone.0297902.ref016","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5694\/mja12.11751","article-title":"Human papillomavirus vaccine in boys: background rates of potential adverse events","volume":"198","author":"HJ Clothier","year":"2013","journal-title":"Med J Aust"},{"issue":"11","key":"pone.0297902.ref017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4070\/kcj.2020.0108","article-title":"Acute Myocarditis in Children: a 10-year Nationwide Study (2007\u20132016) based on the Health Insurance Review and Assessment Service Database in Korea.","volume":"50","author":"J Kim","year":"2020","journal-title":"Korean Circ J."},{"issue":"23","key":"pone.0297902.ref018","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"D Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0297902.ref019","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41598-022-05951-z","article-title":"Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 2014.","volume":"12","author":"M Fu","year":"2022","journal-title":"Sci Rep."},{"issue":"32","key":"pone.0297902.ref020","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.3346\/jkms.2021.36.e232","article-title":"Epidemiology and Clinical Features of Myocarditis\/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study","volume":"36","author":"H Park","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"375","key":"pone.0297902.ref021","doi-asserted-by":"crossref","first-page":"e068665","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study","volume":"375","author":"A Husby","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"pone.0297902.ref022","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciab989","article-title":"Epidemiology of Acute Myocarditis\/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination.","volume":"75","author":"GT Chua","year":"2022","journal-title":"CID"},{"issue":"4","key":"pone.0297902.ref023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"ME Oster","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"pone.0297902.ref024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3988\/jcn.2021.17.2.257","article-title":"Epidemiological Features and Economic Burden of Guillain-Barr\u00e9 Syndrome in South Korea: A Nationwide Population-Based Study.","volume":"17","author":"A Kim","year":"2021","journal-title":"J Clin Neurol."},{"key":"pone.0297902.ref025","article-title":"Relieved co-payment policy.","author":"NHIS","journal-title":"In: NHIS web sites [Internet]"},{"issue":"9","key":"pone.0297902.ref026","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"JC Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"pone.0297902.ref027","article-title":"Forecasting Functions for Time Series and Linear Models forecast.","author":"R Hyndman","journal-title":"In: forecast web sites [Internet]"},{"issue":"1","key":"pone.0297902.ref028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40413-018-0202-7","article-title":"Increasing trends of anaphylaxis-related events: an analysis of anaphylaxis using nationwide data in Taiwan, 2001\u20132013","volume":"11","author":"T-C Yao","year":"2018","journal-title":"World Allergy Organ J"},{"key":"pone.0297902.ref029","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2014.10.021","article-title":"Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992\u20132012","volume":"135","author":"PJ Turner","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"pone.0297902.ref030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/ACI.0000000000000568","article-title":"Gender differences in anaphylaxis","volume":"19","author":"L Salvati","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"pone.0297902.ref031","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.bja.2020.12.020","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","volume":"126","author":"LH Garvey","year":"2021","journal-title":"Br J Anaesth"},{"issue":"6","key":"pone.0297902.ref032","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine.","volume":"51","author":"PA-O Sellaturay","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"pone.0297902.ref033","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/all.15241","article-title":"Allergies and COVID\u201019 vaccines: an ENDA\/EAACI position paper","volume":"77","author":"A Barbaud","year":"2022","journal-title":"Allergy"},{"key":"pone.0297902.ref034","article-title":"Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines.","author":"C Willame","year":"2021","journal-title":"Zenodo"},{"issue":"1","key":"pone.0297902.ref035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","article-title":"Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy.","volume":"38","author":"D Fairweather","year":"2013","journal-title":"Curr Probl Cardiol."},{"issue":"18","key":"pone.0297902.ref036","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/CIRCULATIONAHA.114.010376","article-title":"Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis","volume":"130","author":"V Kyt\u00f6","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"pone.0297902.ref037","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ajem.2016.10.039","article-title":"Sex-based differences in prevalence and clinical presentation among pericarditis and myopericarditis patients.","volume":"35","author":"M Laufer-Perl","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"2","key":"pone.0297902.ref038","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0008-8749(84)90015-7","article-title":"Aggravation of coxsackievirus, group B, type 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb\/c mice and animals treated with progesterone","volume":"87","author":"DC Lyden","year":"1984","journal-title":"Cell Immunol"},{"issue":"11","key":"pone.0297902.ref039","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/jpm11111106","article-title":"Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.","volume":"11","author":"M Li","year":"2021","journal-title":"J Pers Med"},{"issue":"6","key":"pone.0297902.ref040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis With COVID-19 mRNA Vaccines.","volume":"144","author":"B Bozkurt","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"pone.0297902.ref041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000430917","article-title":"A 15-year nationwide epidemiological analysis of Guillain-Barr\u00e9 syndrome in Taiwan.","volume":"44","author":"W-C Huang","year":"2015","journal-title":"Neuroepidemiology"},{"key":"pone.0297902.ref042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CLEP.S199839","article-title":"Guillain-Barr\u00e9 syndrome in Denmark: validation of diagnostic codes and a population-based nationwidestudy of the incidence in a 30-year period.","author":"LS Levison","year":"2019","journal-title":"Clin Epidemiol."},{"issue":"2","key":"pone.0297902.ref043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000339248","article-title":"Guillain-Barr\u00e9 Syndrome Incidence in a Large United States Cohort (2000\u20132009).","volume":"39","author":"IM Shui","year":"2012","journal-title":"Neuroepidemiology."},{"issue":"S5","key":"pone.0297902.ref044","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1007\/s00415-006-5001-3","article-title":"Epidemiology of neuroimmunological diseases","volume":"253","author":"P. Flachenecker","year":"2006","journal-title":"J Neurol"},{"issue":"6","key":"pone.0297902.ref045","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/HYPERTENSIONAHA.121.17316","article-title":"Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination.","volume":"77","author":"S Meylan","year":"2021","journal-title":"Hypertension"},{"key":"pone.0297902.ref046","doi-asserted-by":"crossref","first-page":"n149","DOI":"10.1136\/bmj.n149","article-title":"Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination","author":"I. Torjesen","year":"2021","journal-title":"BMJ"},{"key":"pone.0297902.ref047","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijid.2021.05.021","article-title":"The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout","volume":"108","author":"A Zaqout","year":"2021","journal-title":"Int J Infect Dis"},{"key":"pone.0297902.ref048","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.lanwpc.2022.100442","article-title":"Safety monitoring of COVID-19 vaccines in Japan.","volume":"23","author":"T Yamaguchi","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"6575","key":"pone.0297902.ref049","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1126\/science.abl8487","article-title":"COVID-19 vaccine breakthrough infections","volume":"374","author":"RK Gupta","year":"2021","journal-title":"Science"},{"key":"pone.0297902.ref050","doi-asserted-by":"crossref","first-page":"dyv319","DOI":"10.1093\/ije\/dyv319","article-title":"Cohort Profile: The National Health Insurance Service\u2013National Sample Cohort (NHIS-NSC), South Korea.","author":"J Lee","year":"2016","journal-title":"Int J Epidemiol."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T18:27:12Z","timestamp":1708540032000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297902"}},"subtitle":[],"editor":[{"given":"Yoon-Seok","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0297902","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}